AFFY's only product is Omontys [O], an ESA that has proven itself to harm the patients it was intended to help, namely the sicker chronic kidney disease [CKD] patients whose disease has progressed to the stage where they are on dialysis in a clinical setting three times weekly. In terms of efficacy, O is no better than other ESAs such as Amgen's Epogen, Procrit and Aranesp. In terms of safety, O has proven itself to be unsafe for the healther CKD patients who are not on dialysis, and actual patient usage has proven O to be unsafe for CKD dialysis patients. O's only advantage over other ESA's is that O is administered once monthy compared to weekly for Epogen/Procrit and biweekly for Aranesp. O's once a month dosing advantage is about to be lost to Roche's Mircera, scheduled to be introduced into the US market in mid-2014, which also is administered about once a month.
The AFFY longs, and others manipulating this basically worthless stock, have created the illusion of a binary event when there is no binary event in fact. It is not as if Takeda is now waiting for an FDA decision after submission of a new drug application [NDA]. Instead, Takeda must investigate and determine the cause of O's severe allergic reactions that are so serious patients have died, and as many as 22 patient deaths have been associated with O administration since its limited US 7-month rollout between August 2012 and Feb 2013. The reason O cannot be used for healthier CKD patients, as all other FDA approved ESAs are so used, is because of O's higher number of patients deaths and serious adverse reactions which have been called "inexplicable" and "one for which there is no defenitive answer" by Takeda/AFFY. While Takeda's investigation of O is ongoing, investors have no idea how far it has progressed, how long it will take, or what the results will be. AFFY discloses it will run out of cash by the end of 2nd Q 2014. AFFY faces ruinous class action and products liability litigation.
Is your buddy AE at SA going to answer the counterpoints raised by Walk the Talk in the comment section of AE's last article? It is going on 3 weeks and counting. Or is it possible that he has no counter argument for the issues Walk the Talk has with AE's analyses in his article several weeks ago?
Are your hopes for bk based on a shareholder who paid $11 for 1700 shares?
Do you advise everyone to sell their investments based on shareholder lawsuits?
Are there any companies not being sued by "shareholders" (lawyers looking for business)?
How often have lawyers suing for a $10,000,000 advised their clients to settle for $100,000?
The bigger the number the better the chances of signing up and locking in clients.
Enjoy the rest of December, January's right around the corner.
"AFFY discloses it will run out of cash by the end of 2nd Q 2014."
Caught that just as my last was waiting to post. A lie. A blatant lie. Just shows gwp dosn't know how to interpret english. As for litigation, name one company that doesn't face ruinous class action and products liability litigation, even it was true affy does. Gwp doesn't have a clue as to whether the suits are justified or not. Just that affy faces actions, already well known no new news. Isn't that so, gwp?
Gwp hasn't a clue, though he claims he's a lawyer, just what judgments might come down on the minimal number of suits involved, nor does he have a clue as to whether or not affy's insurance coverage will be sufficient to cover any negative judgments which might occur years from now. Isn't that so, gwp?
A question, gwp. How can you have been a lawyer though you don't know how to interpret english correctly? Were you a lawyer in the US? Is english a 3rd language for you?
Same old gwp Harming the patients it's intended to help. Gwp would have people believe it's more than the, what's the figure?, .02 of 1%?, somebody else can get the right figure up. Compared to the amgens and others of the world, it's certainly no worse. Compared to the amgens and others of the world, it requires a once per month injection vs the multiple injections per week of those others.
Simple numbers, simple story. The gwp's of the world have been unable to prove otherwise. Though they try; man, how they try. #$%$ shawn.